Sofwave Medical

Company Overview

Snapshot

Founded in October 2015, Sofwave Medical is led by co-founders Shimon Eckhouse. The company operates with 51–200 employees and has raised a total of $58.4 million across two funding rounds. Sofwave Medical became public on TASE in May 2021, demonstrating its growth and market validation in the aesthetic medical device sector.

Business overview

Sofwave Medical specializes in non-invasive aesthetic medical solutions, focusing on improving skin laxity, providing lifting effects, and enhancing muscle toning. The company utilizes its proprietary Synchronous Ultrasound Parallel Beam Technology (SUPERB™) to deliver controlled ultrasound energy to stimulate collagen and elastin production. Sofwave's product portfolio includes the Pure Impact add-on module, which offers plyometric muscle activation and toning, complementing treatments like GLP-1 weight loss drugs by preventing muscle loss and improving tone. Clinically validated with multiple FDA clearances, Sofwave Medical serves the rapidly growing aesthetic market, offering effective solutions for patients seeking non-invasive enhancements.

Strategic signal

In May 2026, Sofwave Medical announced the cancellation of its planned Nasdaq IPO, citing improved market conditions on the Tel Aviv Stock Exchange. This strategic decision indicates the company's confidence in its current public listing and suggests a focus on leveraging its existing market position rather than pursuing a dual listing in the near term.

Company Intelligence Q&A

What were Sofwave Medical's financial results for the first quarter of fiscal year 2026?

Sofwave Medical reported its first quarter fiscal year 2026 financial results and business highlights in May 2026.

What were Sofwave Medical's financial results for the fourth quarter and full year 2025?

Sofwave Medical reported its fourth quarter and full year 2025 financial results in March 2026, achieving full-year profitability.

What was the outcome of Sofwave Medical's potential Nasdaq listing in January 2026?

In January 2026, Sofwave Medical was considering a Nasdaq listing, following a 57% increase in fourth-quarter revenue for 2025. However, in May 2026, the company canceled its planned Nasdaq IPO, citing improved market conditions on the Tel Aviv Stock Exchange.

What new product did Sofwave Medical launch in September 2025?

In September 2025, Sofwave Medical launched the Pure Impact VIP™, a standalone device that received 510(k) premarket notification clearance from the FDA. This device extends its Pure Impact™ product line by offering comprehensive muscle strengthening programs for multiple body areas.

What regulatory milestone did Sofwave Medical achieve in Japan in April 2025?

In April 2025, Sofwave Medical received approval from Japan's Pharmaceuticals and Medical Devices Agency to market its SUPERB™ Technology in Japan, significantly expanding its coverage in the APAC region.